• Lytix Biopharma outlined an FDA-cleared plan for a randomized Phase III trial of ruxotemitide with pembrolizumab in resectable high-risk melanoma.
• The agency raised no objection to the study design, supporting a clearer path toward a registrational program.
• Interim Phase II data have already been presented, indicating strong tumor response signals with no relapses reported at the analysis cut.
• Top-line Phase II results are expected in the second half of 2026, shaping partnering talks to fund and run Phase III.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via Cision (Ref. ID: 202608270057BITN____UKPR__EN_20260827-BIT-2791-0) on August 27, 2026, and is solely responsible for the information contained therein.